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Edited by Stuart FergusonAbstract Anandamide and other fatty acid amides are metabo-
lised by the enzyme fatty acid amide hydrolase (FAAH), which
thereby regulates their endogenous levels. Here we demonstrate
that cultured rat cortical microglia express FAAH at low levels.
The potent FAAH inhibitor URB597 reduced the LPS stimu-
lated microglial expression of cyclo-oxygenase 2 and inducible
nitric oxide, with concomitant attenuation of the release of
PGE2 and NO. Additional of supplemental exogenous ananda-
mide did not increase the magnitude of attenuation of mediator
release. The eﬀect of URB597 on LPS stimulated PGE2 release
was not blocked by selective CB1 or CB2 receptor antagonists.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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TNF; URB5971. Introduction
Fatty acid amide hydrolase (FAAH) rapidly degrades
endogenous fatty acid amides including anandamide (arachi-
donyl ethanolamine; AEA) and palmitoylethanolamine
(PEA), both of which have analgesic and anti-inﬂammatory
properties [4,1]. Comparisons of the content of anandamide
and palmitoyl ethanolamine in the brains of wild type and
FAAH knockout mice identify FAAH as a major regulator
of the in vivo concentrations of these fatty acid amides [4,3].
Microglia express several of the known targets of AEA and
PEA [17,11,19], and respond to anandamide by suppression of
various inﬂammatory responses [15,5]. In addition, cultured
microglia have been shown to synthesis anandamide, albeit
at low levels compared with the more abundant endocannabi-
noid 2-arachidonylglycerol [6]. A recent study [12] showed
expression of both FAAH activity and activity of another
endocannabinoid-metabolising enzyme, monoacyl glycerol li-
pase (MGL), by the BV2 microglial cell line and by primary
mouse microglia.*Corresponding author. Fax: +1 858 450 2040.
E-mail address: mwebb5@prdus.jnj.com (M. Webb).
1Present address: Southmead Hospital, Westbury on Trym, Bristol,
BS10 5NB, England.
0014-5793/$32.00  2007 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2007.05.037Here we extend these observations to show not only that cul-
tured rat microglia also express functional FAAH, but also
that inhibition of the enzyme by the FAAH inhibitor
URB597 [14] resulted in a signiﬁcant down regulation of the
expression of the LPS-induced enzymes cyclo-oxygenase 2
(COX2) and inducible nitric oxide synthase (iNOS; NOS2).
These eﬀects were accompanied by a concomitant reduction
in the release of the inﬂammatory mediators prostaglandin
E2 (PGE2) and (NO) nitric oxide. Selective CB1 or CB2 recep-
tor antagonists did not block these eﬀects, suggesting that they
are mediated via other targets of the active mediator whose
concentration is elevated by FAAH inhibition.2. Methods
2.1. Microglial cultures and experimental treatments
Puriﬁed cultures of microglial were prepared using a method modi-
ﬁed from that of Giulian and Baker [7], as described in [16]. Four
hours after plating at 37 C they were treated with either 10 or
20 lM URB597 (Cayman Chemical) in the presence or absence of
the selective CB1 and CB2 antagonists SR141716A and SR144528,
or vehicle (0.05% DMSO/0.06% ethanol). Cells were treated with com-
pounds for 120 min prior to addition of 0.03 lg/ml of lipopolysaccha-
ride (LPS) from Sigma–Aldrich (L3129). After 16 h at 37 C
supernatants were collected for biochemical assays. The microglia
remaining attached to the ﬂoor of the wells were used immediately
to assay for nitric oxide production.
2.2. FAAH and MGL enzyme assay
FAAH activity of microglial cells growing in 96 well plates was
determined by the method of Wilson et al. [18] performed directly in
the culture wells using a ﬁnal [3H]AEA concentration of 160 nM and
a ﬁnal concentration of 10 lM Cay 10400 [1]; (Cayman Chemical
Co, Ann Arbor, Michigan) to set blank values. MGL was assayed
using [3H] 2-mono-oleoyl glycerol (80 nM) as substrate in the presence
of 10 lM Cay 10400 to block FAAH activity.
2.3. RNA preparation and PCR
Total RNA was puriﬁed and reverse transcribed, after which PCR
was carried out with the Expand High Fidelity PCR system (Cat#
1759078, Roche, Indianapolis, IN, USA). The FAAH forward primer
was CTATGGTGTCCCTGTGAGCCT, and the reverse primer was
GAGGGGTCATCAGCTGTTCCAC (predicted band size 1301 bp).
The ampliﬁcation was carried out for 40 cycles at 62 C as the anneal-
ing temperature. Rat FAAH cDNA from recombinant cells was used
as the positive control, no reverse transcription and water as negative
controls.
2.4. Immunoﬂuorescence
Immunoﬂuoresence procedures were as described in [16]. Primary
antibodies and dilutions were: Cayman rabbit anti-FAAH, 1/250;
Serotec mouse anti-CD11b, 1/50; Wako rabbit anti-Iba, 1/250; Second-
ary antibodies were Alexa-ﬂuor anti-mouse or anti-rabbit Ig as appro-
priate.blished by Elsevier B.V. All rights reserved.
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Nitric oxide release from cultured microglia was assessed on live
cells using 4-amino-5-methylamino-2 0,7 0-diﬂuoroﬂuorescein diacetate
(DAF-FM diacetate ;Molecular Probes, USA) in the procedure devel-
oped by Kojima et al. [8] using excitation and emission wavelengths of
490 nm and 520 nm. Prostaglandin E2 (PGE2) and TNF levels were
analyzed using ELISA kits from Cayman and R&D Systems, respec-
tively.
2.6. Immunoblotting
Microglia growing in six well plates were pretreated with 20 lM
URB597 followed by 0.03 lg/ml LPS. After 16 h 20–30 lg of solubi-
lised protein from each sample was analyzed by immunoblotting for
the expression of iNOS and COX-2 using GAPDH as a loading con-
trol. Primary antibodies were: iNOS (BD Biosciences 1:1000), COX-
2 (Cayman Chemical 1:27,000) and GAPDH (Abcam1:1000).
2.7. Statistics
Unless otherwise speciﬁed in the text or ﬁgure legends, all values are
expressed as mean ± standard error of mean (S.E.M., n = 3 individual
experiments each with three to six replicates). Data were analyzed by
analysis of variance (ANOVA) followed by post hoc analysis (Dun-
nett’s test, Prism 4.0, GraphPad, San Diego, CA) and statistical signif-
icance inferred at P < 0.05.-12 -10 -8 -6 -4 -2
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Fig. 1. FAAH expression by microglia. (a) rtPCR detection of FAAH mRN
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Determination of apparent IC50 of URB597 in FAAH activity assay on acu
compound in tissue culture medium. IC50 values were 9.9 and 100 nM, respe
mono-oleoyl glycerol (80 nM) as substrate in the presence of 10 lM Cay 1040
yet exist, non-speciﬁc activity was determined by assaying hydrolysis of cells3. Results
3.1. Expression of FAAH by cultured microglia
By PCR, a diagnostic band of 1301 bp length was seen in
RNA samples prepared from either untreated or LPS treated
microglia, but was absent if water was substituted for RNA
in the cDNA synthesis reaction, or if reverse transcriptase
was omitted from the initial reaction (Fig. 1a).
Both control and LPS treated cells hyrolysed tritiated
anandamide in a reaction blocked by the selective FAAH
inhibitor Cay 10400 (Fig. 1b). The standard assay buﬀer in-
cludes Triton, so the cells are permeabilised during the assay.
In permeabilised cells, this hydrolysis was sensitive to inhibi-
tion by URB597 with an IC50 of about 10 nM (Fig. 1c). Under
conditions mimicking the physiological experiments (incuba-
tion in tissue culture medium followed by assay of residual en-
zyme activity) this IC50 was shifted to 100 nM, with
concentrations in the low micromolar range being required
to achieve inhibitions greater than 90%. We detected MGL
activity as reported by Muccioli et al. [12], but unlike theseb
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A. Samples were run as duplicate reactions: 1, 2 – untreated microglial
ed microglial RNA; 6 – LPS treated microglial RNA omitting reverse
mRNA; 9 – recombinant FAAH RNA omitting reverse transcriptase;
(b) Expression of FAAH enzyme activity by cultured microglia. Data
ctivity (10 lM of the potent selective FAAH inhibitor CAY10400). (c)
tely permeabilised microglial cultures or intact cells preincubated with
ctively. (d) Monoacyl glycerol lipase activity was assayed using [3H] 2-
0 to block FAAH activity. Since no selective inhibitors for this enzyme
brieﬂy ﬁxed in 4% paraformaldehyde.
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trations of URB597 up to 10 lM (Fig. 1d).
More than 95% of the cells stained with the microglial mark-
ers CD11b or Iba (Fig. 2a,b). As shown in Fig. 2c, a low but
speciﬁc staining was seen with the Cayman anti-rat FAAH
antibody in essentially all cells. This staining was not seen if ﬁrst
antibody was omitted (Fig. 2d), and co-localised with CD11b
expression (Fig. 2e,f). Since almost all of the cells are microglia,
and almost all stain with FAAH antibody, and co-localisationFig. 2. Immunoﬂuorescent detection of FAAH in single microglia. Greater th
with the selective microglial markers CD11b (a) or iba (b). Fewer than two p
less than 24 h after plating. Low but distinct and speciﬁc FAAH activity was
antibody abolished this ﬂuorescence (d, same exposure as c). (e, f) Three cel
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Fig. 3. Eﬀect of URB597 on LPS stimulated PGE2 release. (a) Inhibition of L
mediated attenuation of LPS stimulated PGE2 release was not blocked by
*P < 0.05% vs. LPS.with a microglial marker was observed, we conclude that
FAAH is indeed expressed by microglia in these cultures.
3.2. URB597 inhibition of LPS stimulated COX2 expression and
PGE2 release
For all the experiments reported here, LPS was used at a
concentration of 0.03 lg/ml.
The vehicle used for addition of URB597 and the selective
CB1 and CB2 antagonists was DMSO (ﬁnal concentrationan ninty-eight percent of the cells in the enriched cultures were stained
ercent of the cells in the cultures were small GFAP+ astrocytes at times
detected in essentially all the cells in the culture (c). Omitting the ﬁrst
ls in which FAAH staining is co-localised with CD11b staining.
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Fig. 4. Eﬀect of URB 597 on LPS induced COX-2 and iNOS expression. Upper panels: immunoblots of samples from control, LPS treated, and
LPS + URB597 (20 lM: FAAHi) treated microglia. GAPDH was used as a loading control. Lower panels; blot quantitation from n = 2 independent
experiments with mean and range.
Table 1
Summary of mediator release experiments
Assay 10 lM URB 10 lM URB +
20 lM AEA
20 lM URB
PGE2 51 (11.3); n = 3 47.5; n = 1 56; 61 n = 2
NO 71 (16.4); n = 3 64; 73; n = 2 67; n = 1
TNF 79.2 (10); n = 4 72; n = 1 74 (5.3); n = 3
Figures are percentage inhibitions of mediator release by URB 597 at
10 lMwith or without additional anandamide (20 lM) supplement, or
20 lM URB 597 without additional anandamide compared with LPS
stimulated microglia in the same experiment; brackets are standard
deviations, n = total number of experiments for speciﬁed condition.
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(ﬁnal concentration 0.6%). A mix of 0.1% DMSO and 0.6%
ethanol had no eﬀect on the levels of release of any of the medi-
ators we examined.
Stimulated levels of PGE2 were elevated approximately 4-
fold over unstimulated controls (Fig. 3), corresponding to a
strong up regulation of COX2 expression (Fig. 4a). Treatment
with 10 lM URB597 reduced the release of PGE2 to approx-
imately 50% of control values, but we saw no reproducible ef-
fect at 2.5 or 5 lM. Neither addition of 20 lM anandamide
nor increasing the URB597 concentration signiﬁcantly in-
creased the degree of inhibition. Concomitant treatment with
the selective CB1 receptor antagonist SR 141716A or the
CB2 antagonist SR144528 (both at 10 lM) did not reverse
the eﬀect of URB597 (Fig. 3b) Treatment with 20 lM
URB597 during the stimulation period reduced the expression
of COX2 to a mean of 51% of LPS treated controls.Co
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the time of LPS stimulation produced no reduction in NO re-
lease (not shown), while 10 lM URB597 produced somewhat
variable inhibition between experiments (71% S.D. = 16.4;
n = 3; Table 1). In two separate experiments, supplementing
10 lM URB597 with 20 lM anandamide produced a similar
mean level of inhibition but with lower inter-experiment vari-
ability (64%; 73%). Increasing the concentration of URB597
to 20 lM did not signiﬁcantly increase the degree of inhibition
observed. URB597 treatment throughout the induction period
reduced the expression of the iNOS band to a mean of 70% of
LPS treated controls (Fig. 4b) in immunoblotting experiments.
TNF release was also attenuated modestly (Fig. 5b and Table
1).4. Discussion
While this work was in progress, the expression of FAAH by
the microglial cell line BV2 and by primary cultured mouse
microglia was reported [12]. We demonstrated that cultured
rat primary microglia also express FAAH using three ap-
proaches, PCR, the detection of pharmacologically character-
istic enzyme activity, and immunoﬂuoresence on individual
cells. All approaches concurred in suggesting that the enzyme
is expressed, albeit at relatively low levels, by both unstimu-
lated and LPS treated microglia. We used immunoﬂuorescence
methods to show that essentially all cells in the cultures (95%
of which are microglia) express the enzyme, and that FAAH
staining co-localised with cells expressing microglial markers.
URB597 treatment of the microglia concomitant with LPS
treatment reduced the release of PGE2 and NO, and this cor-
related with a reduced expression of the enzymes COX2 and
iNOS, respectively. Preliminary experiments indicated
URB597 concentrations of 10 lM were required to see these
eﬀects reproducibly, and no signiﬁcant potentiation of the ef-
fect was seen by concomitant addition of exogenous ananda-
mide (20 lM). In acute anandamide hydrolysis assay of
permeabilised cells, URB597 had an IC50 value of about
10 nM, which was shifted to 100 nM, if we exposed the cells
to the compound under conditions mimicking the physiologi-
cal inhibition experiments. Although we needed concentrations
of URB597 of 10 lM to achieve signiﬁcant and reproducible
inhibition of PGE2 and NO release, it should be noted that
at this IC50, low micromolar concentrations would be required
to inhibit 90% or more of this activity. Such levels of inhibition
may be required before signiﬁcant accumulation of substrate
occurs (our unpublished observations). Similar to the report
of Muccioli et al. [12], we found that microglia expressed a
MGL-like activity, but in our hands this was insensitive to
URB 597 concentrations up too 10 lM. We therefore, believe
that it is most likely that inhibition of FAAH, rather than
microglial MGL, is responsible for the anti-inﬂammatory ef-
fects of URB 597 we observed.
Selective CB1 or CB2 antagonists did not abolish inhibition
of PGE2 release by URB 597. Anandamide is known to be an
agonist at additional non-CB1 non-CB2 targets some of which
are expressed by microglia [2,10], so this observation is not
inconsistent with a mechanism by which FAAH inhibition re-
sults in accumulation of anandamide (or other endocannabi-
noid) which then mediates the observed reduction in
mediator release. The hypothesis that FAAH-regulated lipidscan exert a cannabinoid receptor-independent eﬀect on inﬂam-
matory responses is supported by the non-CB receptor medi-
ated anti-oedema eﬀects seen in FAAH knockout mice after
formalin injection [9].
We did not test the eﬀect of selective CB receptor antago-
nists on release of NO or TNF, so it remains a possibility that
they may play some role in the release of these mediators.
The maximum levels of inhibition we observed were of the
order of 40–50% for both PGE2 and NO, and, more modestly,
25% for TNFa. These values are similar to those reported for
microglial iNOS expression and NO release by Ortega-Gutti-
erez et al. [13], using the putative anandamide transporter
UCM707. Whether such levels of inhibition could translate
into a therapeutically useful eﬀect in any given pathological
condition can only be evaluated in vivo, where the microglia
are functioning in a complex milieu including other cellular
sources of fatty acid amide mediators.
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